Pharmaceutical security spends heavily on the systems that hold research and trial data, and comparatively little on the sprawling external correspondence those systems depend on — CROs, investigator sites, agency portals, patient programmes and contract manufacturers, all exchanging links daily. This page is about applying a DNS-verified list of live phishing hosts to that correspondence without disturbing a validated system.
Pharmaceutical phishing is rarely opportunistic and almost never financial. It is targeted access to a specific body of work, and it is designed to be silent for as long as possible.
Most sectors experience credential theft as an event with a visible consequence — money leaves, systems encrypt, somebody notices. In pharmaceutical research the useful outcome for an attacker is the opposite: quiet, sustained read access to a programme. Structure-activity data, assay results, formulation and process detail, stability studies, statistical analysis plans, interim safety data, the contents of a regulatory dossier ahead of submission. None of that has to be exfiltrated in a dramatic burst. It can be read over months by somebody holding a valid session in a collaboration platform, and the theft leaves no operational symptom at all.
Post-hoc detection is much weaker here than in a sector where a breach announces itself, because the interval between compromise and discovery can be an entire development phase. Prevention at the point of the click is proportionally more valuable, and prevention that works without depending on a scientist correctly evaluating a hostname is more valuable still — because the population being targeted is not naive, it is busy, and the lures are built specifically around the rhythms of their work.
Clinical trial registries publish sponsors, sites, principal investigators and phases. Conference programmes publish who is presenting what. Journals publish corresponding authors with institutional addresses. Regulatory dockets publish submission activity. Partnership and licensing announcements publish exactly which two organisations are now exchanging confidential material. Nobody has to guess who talks to whom; the industry documents it as a matter of professional practice, and correctly so.
They are a manuscript-revision request that references a real paper, a site-initiation document from a CRO the recipient genuinely works with, a query from a regulator during a live review, a data-transfer notification from a lab the team really uses. Each is entirely plausible in isolation, and each resolves to a hostname that is very nearly right. The only reliably machine-checkable fact in the whole sequence is that hostname.
A modern study is a federation. The sponsor holds the protocol; a contract research organisation runs operations; central labs process samples; imaging vendors read scans; an interactive response system handles randomisation; investigator sites recruit and treat. Every one of those is a separate company with its own mail platform, its own joiners and leavers, and its own security maturity — and every one of them exchanges documents with your staff several times a week.
Four legitimate senders. Four unfamiliar hostnames. No cue that separates them from a fifth.
A query arriving mid-assessment, with a deadline, pointing at a gateway that is not the real one. Regulatory affairs is trained to answer these fast.
Notice of an upcoming site inspection with a document request attached. Nothing concentrates attention at a manufacturing site faster.
Aimed at the pharmacovigilance mailbox, which is published by obligation and monitored continuously by people who must never ignore anything.
A notice that a submission gateway account will lapse before a filing date, which is the one thing nobody in regulatory affairs will risk.
Regulatory affairs functions are built to be responsive. Deadlines during a review are real, clock-stops have commercial consequences, and a delayed reply to an information request is a professional failure with visibility all the way up the organisation. That responsiveness is a strength of the discipline and the exact lever the impersonation uses.
The properties that matter in a regulated environment are determinism, provenance and a stable update cadence. This is what the database provides on each.
Determinism is the property a validated environment cares about most, and it is the one most threat products cannot offer. A response here carries is_phishing, a category of phishing/malware, a dns_status of resolves, a last_checked date and a confidence of exactly 0.98 for a confirmed match or 0.0 for no match. There is no intermediate score, no model drift between releases, and no scenario in which the same input produces a different class of answer for reasons nobody can reconstruct. When a quality function asks what the control does and how its output is interpreted, that specification fits on one page and does not change.
Inclusion requires an active A record confirmed through rotating proxy infrastructure, so the file describes hosts that are resolving rather than hosts that were once reported, and entries that go dark fall out instead of accumulating. That matters operationally as well as philosophically: a blocklist that only grows eventually blocks something a laboratory needs, and in an environment where changing a control means raising a change record, an unnecessary false positive is expensive out of all proportion to its technical significance.
The database rebuilds every 24 hours with the build landing at 04:30 UTC, and a changelog of domains added and removed ships alongside it. A controlled environment can therefore describe its update process precisely — a scheduled retrieval, a defined diff, an approved reload window, a recorded file version — rather than describing a vendor pushing unspecified changes into a system on an unspecified schedule. That distinction is the difference between an easy change-control conversation and a hard one.
/stats endpoint reports database size and last update with no API key, no credits and no authentication, which makes it usable as an independent currency check.The same brand that appears on a package insert appears in domain names built to sell something that is not the product, or to harvest the details of somebody trying to obtain it.
Brand impersonation in pharmaceuticals differs from most sectors in who gets hurt. When a consumer brand is cloned, the loss is money and trust. When a medicine brand is cloned, the person on the other end may take a substance of unknown composition, or may fail to take the real one because they believe they have already ordered it. The exposure is therefore a patient-safety matter with a communications dimension attached, and it tends to be owned by a brand protection or legal function that is organisationally distant from the security team holding the relevant tooling.
The product brand paired with a commercial qualifier — buy, order, generic, discount, price, online. The brand paired with an access qualifier — savings, copay, assistance, support, coupon, programme. The brand under a top-level domain the company has never registered, convincing precisely because patients have no idea which suffix is genuine. And plain typographic variants of a product name that is already unfamiliar and hard to spell, which is a category most medicine brands fall into by design.
They exist to help patients with reimbursement, adherence and access; they collect exactly what an identity-fraud operation wants — full name, date of birth, insurer, prescriber, diagnosis — and they are frequently run by a third-party administrator on a domain that is not the manufacturer's. Patients have no way to tell a genuine programme address from a fabricated one, because the genuine one already looks unrelated to the brand. Consolidate onto one hostname per programme, publish it on packaging and prescriber materials, and never vary it for a campaign.
You cannot block a page for a patient on their own connection. You can take candidate hostnames — from watch services, a registrar feed, patient reports, or your own permutation generation — and get a definite, dated answer on which are confirmed live phishing infrastructure. That is the evidence that moves a takedown forward, and the evidence you want before publishing any warning to patients. Run the candidates through the batch endpoint at a hundred domains per request, one lookup each, from a server-side job; the wider approach is on our brand protection page.
Medical information teams, patient-programme staff, sales representatives and contact-centre agents all handle patient contact and all resolve through infrastructure you control. Loading the same confirmed hostile hostnames at the resolver protects that population automatically, and it also stops an employee inadvertently validating a counterfeit storefront while investigating a report — which is a surprisingly common way for a fake address to acquire internal credibility.
The technical options are ordinary. The constraint that decides between them is change control, and it points firmly at the infrastructure layer.
| Consideration | Network resolver / firewall | Mail gateway | Inside a validated application |
|---|---|---|---|
| Change-control burden of a daily update | Infrastructure data, not application logic | Security tooling, normally outside validation scope | Touches a qualified system; expect assessment each time |
| Coverage of laboratory and office endpoints | Everything that resolves through it | Mail-borne links only | One application's users |
| Covers external partner correspondence | On the click, wherever it originated | At delivery, before the click | No |
| Effect on qualified instrument workstations | None — no agent, no software change | None | Direct, and therefore assessable |
| Works for a manufacturing or OT segment | Yes, as an egress deny list | Only where those users have mail | Rarely applicable |
| What leaves the network | Nothing — matching is local to the feed copy | Nothing, if fed from the local copy | Depends on the integration |
| Best role | Primary enforcement across the estate | Earliest interception for partner mail | Reserve for a specific, justified case |
The argument that usually wins internally is the one about scope. A blocklist loaded into a resolver or a firewall is reference data consumed by infrastructure, in the same category as a threat signature set or a certificate revocation list. It does not alter the configuration, the code or the intended use of any qualified application, and the workstations attached to an instrument are unchanged — no agent, no installation, no revalidation trigger. Embedding the same lookup inside a laboratory information management system or an electronic data capture platform is a different proposition entirely, because you have then modified a system whose qualified state you are obliged to maintain, and every daily data update becomes an event somebody has to reason about.
Those networks are typically flat, long-lived, and full of equipment that cannot be patched on any normal cadence, and they frequently retain some egress path for vendor support or telemetry. A deny list applied at the segment boundary is one of the few controls that can be added there without touching the equipment, and because the list is a static file consumed at the boundary, its introduction is a network change rather than a system change. The reasoning parallels what we describe for manufacturing environments generally.
It is the part a quality reviewer will ask about, so draft it before switching anything on: a defined retrieval window shortly after the 04:30 UTC build, a recorded file version, application of the published changelog rather than a blind full reload, a rollback path to the previous file, and an alert if the loaded file exceeds forty-eight hours in age. That description is short, testable and stable — which is exactly what makes it easy to approve and easy to keep approved.
An order of work that follows the risk rather than the org chart, and the two pricing mechanisms that cover it.
Start where the correspondence volume and the data sensitivity intersect, which is clinical operations and data management rather than the research campus. Those teams exchange the most external mail with the most partners, and they are the population reached by CRO and site impersonation. Screening inbound links at the mail gateway for that group, in flag-only mode for a few weeks, produces a hit rate from your own traffic and gives the security function something concrete to take to a governance forum.
Adding the resolver converts a mail control into an estate control and covers the click that arrives by any other route — a messaging platform, a document shared by a partner, a search result during an investigation. It is also the step that reaches instrument workstations and shared laboratory terminals, which mail screening never touches. After that, extend to the pharmacovigilance and medical information mailboxes, the manufacturing segment boundary, and the periodic sweep of hostnames you publish yourself.
Credits are monthly subscriptions via PayPal, billed monthly, with unused credits expiring at that point: Growth at $99/month for 25,000 lookups, Growth at $99/month for 25,000 lookups , Professional at $249/month for 100,000 lookups with priority support, Business at $499/month for 250,000 lookups with dedicated support, and larger tiers at $999/month for 750,000 lookups, Enterprise at $999/month for 750,000 lookups and Enterprise at $999/month for 750,000 lookups with an SLA. A fourteen-day refund applies where under ten percent has been used, and above $4,000 bank transfer is available.
The Daily Threat Feed is $499 per month or $499/month and adding historical archive access, priority support, custom format options, a dedicated account manager and 100,000 API credits — which in practice funds the brand verification and link sweeps above. Downloads are unlimited, so a global estate with resolvers on several continents costs the same as a single site. Delivery via SFTP, S3, STIX/TAXII or on-premise is quoted; the full table is on the pricing page and formats under daily feed.
Including the objections from quality assurance, which are the ones that decide whether anything actually gets deployed.
Not when it is deployed at the network or mail layer, which is the recommended pattern for precisely this reason. A blocklist consumed by a resolver or a firewall is reference data used by infrastructure. It does not change the configuration, code or intended use of a qualified application, and it installs nothing on an instrument workstation. Embedding the lookup inside a validated application is a different matter and will be assessed as a change to that system. If a specific workflow genuinely justifies it, treat it as an application change with the usual impact assessment — but for most organisations the infrastructure placement gives the same coverage with none of that burden.
Validate the process, not each day's content, which is how organisations already handle antivirus definitions and certificate revocation data. Write a procedure covering the retrieval window after the 04:30 UTC build, the file-version record, the application of the published changelog rather than a blind full reload, the rollback path to the previous file, and the alert threshold for a stale file. That gives a reviewer a defined, testable and stable process. The daily diff is what makes it clean: you can state exactly what changed on any given day and reproduce the list in force on any past date, which is the question that actually comes up during an investigation.
Not on its own, and any claim otherwise should be treated with suspicion. A well-resourced adversary targeting a specific programme will register infrastructure shortly before use, sometimes hours before, and a known-bad list cannot contain a domain nobody has observed yet. What it removes is the substantial tail of reused and commodity infrastructure that appears even in targeted campaigns, at a cost and operational weight far below a detection platform. Treat it as a floor that eliminates the cases already proven, then spend your remaining effort on the controls that address novel infrastructure — phishing-resistant authentication for research platforms, segmentation, and monitoring for anomalous access to programme document sets.
Directly, no — you cannot enforce on a hospital's network or a vendor's laptops. There are three indirect routes that do work. First, contractual: vendor qualification and quality agreements can require link screening and specify the named domains used for study correspondence. Second, architectural: publish one sponsor portal hostname and refuse to create study-specific variants, so site staff have a single thing to recognise. Third, evidential: when a site reports a suspicious message, verify the hostname and give them a definite dated answer rather than an opinion.
Usually more relevant than the description suggests, because "no internet access" rarely survives contact with the actual routing table. Vendor remote support, historian replication to a corporate data lake, licensing checks, cloud-connected environmental monitoring and engineering laptops that move between segments all tend to produce egress paths that were justified individually and never reviewed together. A deny list at the segment boundary costs nothing to add, touches no equipment, and constrains where anything in that segment can reach if something does get in. If the segment genuinely has no egress at all, this control has nothing to do there — but confirm that from the firewall rules rather than from the network diagram.
It verifies candidates; it does not discover them. This is a lookup service, not a brand-monitoring platform, and the distinction matters when scoping. You supply hostnames — generated from permutations of your brand names, taken from a registrar watch, or reported by patients and field staff — and receive a dated verdict on which are confirmed live phishing infrastructure. That is the input a takedown request needs, and it is also the safest basis for deciding whether to warn patients. Note the boundary honestly: a storefront selling counterfeit product without harvesting credentials may not be classified as phishing at all, so this is one input to a counterfeit programme rather than the programme itself.
Because the coverage does not overlap as much as it appears. Mail platforms defend the mail channel. A great deal of pharmaceutical correspondence does not arrive by mail — links come through partner collaboration platforms, messaging tools, shared document systems and search results during an investigation, and none of that passes a mail gateway. Loading the same verified list at the resolver extends one decision to every channel and every device on the network, including laboratory terminals that have no mailbox at all. It also removes the dependency on link-rewriting behaviour, which varies by platform and is routinely bypassed when a link is forwarded outside the original message.
Plan the correction path before you enable enforcement, because in this environment the delay is the cost. Maintain a local allow-list that your reload applies after each import so an override survives the next update, name the security contact on the block page, and set an internal response target that reflects the fact that the person blocked may be facing a submission deadline. Verification through an active DNS check keeps the false-positive rate low, and because entries fall out when they stop resolving, a compromised partner site that gets cleaned up disappears from the list without anyone having to remember to remove it. Even so, the correction path matters more than the error rate, and it is worth rehearsing once rather than discovering it during a filing week.
Screen inbound links for clinical operations and regulatory affairs, load the feed at the resolver for the rest of the estate, and keep credits for brand verification and periodic sweeps. None of it touches a qualified system.
